Jay Goldberg, MD, ob-gyn at Einstein Medical Center of Philadelphia, outlines treatment options for uterine fibroids in patients with different needs.
Contemporary OB/GYN:
Please introduce yourself and outline your lecture on uterine fibroids for Symposia Medicus.
Jay Goldberg, MD:
Hi, I'm Jay Goldberg. I'm an ob-gyn at Einstein Medical Center, Philadelphia, which is part of the Jefferson Health Network. I'm also the director of the Philadelphia Fibroids Center. The talk that I gave earlier today looked at different treatments for fibroids. We talked about patients desiring fertility and those not desiring fertility, talked about whether the patient's symptomatic or asymptomatic, and the symptoms they'd have, whether it's bleeding symptoms, bulk symptoms, or fertility symptoms, and how that can guide you in recommending appropriate treatments for the patients. We talked about options as far as expected management, which may be the appropriate thing for half the patients. We talked about medical treatments. We talked about progestin IUDs that may help patients not desiring fertility, who mainly have bleeding issues. We also talked about uterine fibroid embolization, which is a procedure, especially for somebody who does not want fertility, which can decrease volume of fibroids by about 40% by 3-dimensional volume and improve their bleeding. And we also talked about surgical treatments for fibroids.
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More